Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

PhoreMost Enters Multi-project Drug Target Discovery Collaboration with Roc

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world’s leading biotechnology companies.

Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, toward disease-relevant pathways nominated by Roche. Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.

The SITESEEKER® platform is based on PhoreMost’s core proprietary ‘Protein Interference’ (PROTEINi®) technology. PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. SITESEEKER® systematically unmasks new and unanticipated druggable sites across the entire human proteome, directly linking them to useful therapeutic functions.

Dr Neil Torbett, CEO of PhoreMost, said:This collaboration with Roche is testament to the power and versatility of SITESEEKER, and further validates the potential and broad applications of the platform. We are delighted that Roche has chosen to work with us to enhance its drug discovery pipeline using PROTEINi and SITESEEKER to identify novel targets and unlock the power of protein structure prediction for next generation drug design.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine